Amarin Corporation PLC (AMRN)vsAstraZeneca PLC (AZN)
AMRN
Amarin Corporation PLC
$13.93
+0.94%
HEALTHCARE · Cap: $303.42M
AZN
AstraZeneca PLC
$185.95
-1.94%
HEALTHCARE · Cap: $282.69B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 27783% more annual revenue ($60.44B vs $216.76M). AZN leads profitability with a 17.2% profit margin vs -15.5%. AMRN appears more attractively valued with a PEG of 0.81. AZN earns a higher WallStSmart Score of 64/100 (C+).
AMRN
Hold43
out of 100
Grade: D
AZN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+88.8%
Fair Value
$134.34
Current Price
$13.93
$120.41 discount
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Growing faster than its price suggests
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
ROE of -7.5% — below average capital efficiency
Earnings declined 94.2%
Distress zone — elevated risk
Moderate valuation
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AMRN
The strongest argument for AMRN centers on Price/Book, Debt/Equity, PEG Ratio. PEG of 0.81 suggests the stock is reasonably priced for its growth.
Bull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : AMRN
The primary concerns for AMRN are Market Cap, Return on Equity, EPS Growth.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Key Dynamics to Monitor
AMRN profiles as a turnaround stock while AZN is a mature play — different risk/reward profiles.
AMRN carries more volatility with a beta of 0.82 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 43/100), backed by strong 17.2% margins and 12.5% revenue growth. AMRN offers better value entry with a 88.8% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Amarin Corporation PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Amarin Corporation plc, a pharmaceutical company, is engaged in the development and commercialization of therapies for the treatment of cardiovascular disease in the United States. The company is headquartered in Dublin, Ireland.
Visit Website →AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?